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Paraneoplastic syndromes (PNS) are a heterogeneous group of symptoms which are indirectly caused by primary or metastatic
tumor. Paraneoplastic polyneuropathy (PNP) is mostly related to small cell lung cancer (5%), prostate, gastric, and breast cancer.
Only sporadic cases have been reported to be associated with endometrial cancer. We present a case of a premenopausal woman
with severe vasculitic, asymmetric sensorimotor polyneuropathy that developed in conjunction with an endometrial carcinoma
responding to surgical therapy of primary tumor combined to steroid therapy. Neurological symptoms such as asymmetrical
sensorimotordeﬁcitsandpainfulparesthesiasaresuspiciouswhentheyoccurinotherwisehealthywomenwithnomedicalhistory.
The phenomenon of a paraneoplastic syndrome can point to an underlying malignancy and can be used as marker of progression
or regression of the tumor. Due to the rarity of PNP, there is no standard treatment. Recommended therapy is stage-adjusted
treatment of the primary tumor.
1.Introduction
Paraneoplastic neurologic disorders (PNDs) are remote ef-
fects of the cancer aﬀecting any part of the central or
peripheral nervous system, presenting with diverse symp-
toms. Common features of PNDs are usually rapid devel-
opment, severity of the neurological illness, and appearance
before the cancer diagnosis. According to the most widely
recognized theory, the genesis is believed to be autoimmune
mediated. An autoimmune response of the organism to
antigens expressed by tumor cells is assumed. The antigens
cause the body’s immune system to produce antibodies in an
attempt to suppress the cancer. These same antibodies can
trigger an autoimmune attack on the brain and the neuro-
logical systems [1]. The exact pathophysiological principles
are not yet fully understood [2].
The incidence of paraneoplastic polyneuropathy (PNP)
ﬂuctuates between 10–40% among all patients with cancer
[3], depending on diagnostic criteria. PNP is usually associ-
ated with small cell lung carcinoma, prostate, gastric, colon,
or breast cancer, and lymphoma [4].
We report the particular case of a female patient with
progressive vasculitic PNP associated with endometrial can-
cer presenting as severe asymmetrical sensorimotor deﬁcit
resembling a mononeuritis multiplex and proximal motor
weakness.
2.CaseReport
A 48-year-old, premenopausal Caucasian nulli gravida, was
admitted to the Neurological Department of Aachen Univer-
sity Medical Center, complaining of weakness of upper and
lower extremities and severe peripheral hypesthesia.
The onset of the patient’s symptoms started 3 months
before the ﬁrst admission to the hospital with hypesthesia
and pricking paresthesia in upper extremities. The patient
gradually developed a severe distal accented loss of muscle
power, according to the Medical Research Council Score
(MRC) for evaluating peripheral muscle strength 3/5 for
upper extremities and 2/5 for lower extremities. All extrem-
ities were aﬀected by severe hypesthesia, the pallesthesia2 Case Reports in Obstetrics and Gynecology
Figure1:Semithinsectionofthesuralnerveshowingasubtotalloss
ofmyelinated nerveﬁbres.(Semithintoluidinebluesection, ×40oil
immersion).
Figure 2: Vasculitis: CD68 immunoreactive macrophages within
the epineurium. (Semithin toluidine blue section, ×40 oil immer-
sion).
was preserved. At the time of the hospital admission she
was conﬁned to a wheelchair and unable to attend to own
bodily needs without assistance (modiﬁed Rankin scale 4/6).
The patient’s medical history did not reveal any suspicious
ﬁndings.
Peripheral blood laboratory parameters such as elec-
trolytes, blood clothing, renal and liver function panel, TSH,
CRP, homocystein were in normal range except for elevated
lipase (68U/L) and leukocytosis (20,6G/L). The special
extended immunology blood tests were performed. The fol-
lowing targeted parameters have been discovered to be neg-
ative: ANA, ds-DNS Ab, ANCA Screening, AMA/LKM-
1 Ab Screening, cryoglobulins, and cold agglutinins. The
screening for antineuronal antibodies—Anti-Yo,Hu,Ri—was
negative. A mild protein elevation 0.59g/L (normal range:
0.21–0.42g/L) was found in the cerebrospinal ﬂuid, without
evidence of active infection.
The nerve conduction studies (NCSs) showed no sensory
nerve action potential in radial and sural nerve; motor
NCS in tibial and median nerve demonstrated slightly
decreased conduction velocities with decreased amplitude of
the compound muscle action potential (CMAP). The elec-
tromyelography (EMG) of the anterior tibial muscle did not
reveal any spontaneous activity. The results pointed to an
asymmetrical miscellaneous sensorimotor polyneuropathy
with no evidence of a central motor pathways damage.
In search of a primary tumor cranial/spine MRI and CT
thorax/abdomen were performed without any pathological
ﬁndings.
Suralnervebiopsyrevealedanadvancedaxonal/neuronal
neuropathy with a moderate microangiopathy (Figures 1
and 2).
Under the impression of an etiologically unexplained
progressive sensorimotor neuropathy corticosteroid therapy
(75mg per day) and symptomatic therapy with pregabalin
(150mg twice a day) was started.
The gynecological examination because of meno-/met-
rorrhagia showed an heterogenous and suspicious en-
dometrium. The patient underwent a hysteroscopy with
fractional abrasion of the uterus. The histology conﬁrmed a
moderately diﬀerentiated adenocarcinoma of endometrium,
four months after the onset of the ﬁrst neurological symp-
toms. An abdominal hysterectomy with bilateral adnex-
ectomy was performed. The postoperative histopathology
revealed a G2 endometrioid adenocarcinoma of the uterine
corpus with the tumor inﬁltration less than half the myome-
trial thickness without cervical or parametrial involvement,
but with peritumoral lymphangiosis carcinomatosa. UICC
Classiﬁcation 2010: G2, pT1a, pNx, pMx, L1, R0. FIGO
Stage IA. The interdisciplinary tumor board decided on
performing the completing systematic pelvic and paraaortic
lymphadenectomy. 4 lymph nodes (pelvic/ paraaortic) from
25 lymph nodes were inﬁltrated. The ﬁnal classiﬁcation
of the tumor was G2, pT1a, pN1 (4/25), L1, R0 (local).
FIGOStageIIIC2.AccordingtotheGermaninterdisciplinary
oncologic guidelines an adjuvant radiotherapy combined of
paraaortic irradiation with total dose of 45Gy, parametrial
50, 4Gy, and vaginal afterloading twice, 8Gy, was accom-
plished.
During the tumor complex treatment an intensive phys-
iotherapy was performed. The duration of the corticosteroid
therapy was one month until the hysterectomy with bilat-
eral adnexectomy was performed. To reach better wound
healing after the operation prednisolone dose was decreased
to 10mg/die and 7,5mg/die for 2 months and after all slowly
tapered.
The ﬁnal neurological examination showed an improve-
ment in the motor function in all limbs—Medical Research
Council Score (MRC) 4/5 for upper extremities and 3/5 for
lower extremities. Furthermore the distal hypesthesia of all
extremities persisted. The nerve conduction study veriﬁed
the clinical ﬁnding—almost normal amplitudes and amelio-
ration in velocities in motor tracts. The sensory nerve action
potential in lower extremities was still absent.
3. Discussion
We introduced a patient with adenocarcinoma of uterus
detected through the manifestation of a paraneoplastic neu-
rologic disorder, showing a progressive sensorimotor vas-
culitic polyneuropathy. The main diﬀerential diagnoses
of PNP are diabetes, alcoholism, neurotropic infection,
metabolic, autoimmune or toxic cause, and traumatic lesionCase Reports in Obstetrics and Gynecology 3
[5]. After excluding other causations of the polyneuropathy
[6] in otherwise healthy patient the most reasonable cause
was paraneoplastic, although the screening for antionconeu-
ral antibodies was negative. Therefore arguments in favor of
ar e m o t ee ﬀect of cancer can only be drawn from indirect
criteria. Unfortunately, not all the patient with PNS have
identiﬁable antibodies in their serum [7]. According to Rees
[8] the absence of antionconeural antibodies cannot exclude
the presence of PNS.
Peripheral neuropathies are among the most common
neurologiccomplicationsofcancer.PNPiscommonlyfound
associated with neoplasms like small cell lung carcinoma,
small cell carcinoma of prostate, pancreatic, colon, breast,
and gastric cancer. PNP occurs seldom with cancer of female
genital organs. Rojas-Marcos et al. [9] reviewed 92 patients
with PNSs associated with gynecologic or breast cancer.
There was no case of endometrial cancer combined with
PNP. Ashour et al. [10] studied 122 reports of gynecologic
cancerpatientswithPNSsandfoundonecaseofendometrial
cancer presenting as paraneoplastic polyneuropathy with
predominantly motor manifestation [11], other cases were
related to ovarian cancer [12]. The most successful therapy
nowadays is resection of the tumor and/or oncological
therapy [13, 14].
4. Conclusion
AlthoughtheoccurrenceofPNPandendometrialcarcinoma
is rare, it can lead to severe clinical signs and may lead
to emergency cases. PNP can occur before the neoplastic
diseases are detectable, therefore, the prompt recognition of
paraneoplastic symptoms facilitates early tumor diagnosis
and the timely treatment of tumor and paraneoplastic syn-
drome. The therapy of PNP itself is not yet standard-
ized because of disease heterogeneity, rarity, and various
stages of primary tumor. Corticosteroids, azathioprine,
cyclophosphamide,intravenousimmuneglobulin,andother
immunomodulatory therapies are tested, but the results are
still unsatisfactory. The supplementary symptomatic therapy
should be used to alleviate of disabling neurologic symptoms
of the patients. Last but not least, immunomodulatory ther-
apy can hypothetically inﬂuence tumor growth.
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